New drug duo aims to shrink esophageal tumors before surgery
NCT ID NCT06654297
First seen Apr 02, 2026 · Last updated May 20, 2026 · Updated 9 times
Summary
This early-phase trial tests whether combining two drugs, camrelizumab and palbociclib, is safe and feasible for patients with a type of esophageal cancer that can be surgically removed. The drugs are given before surgery to try to shrink the tumor. The study involves 6 participants and focuses on side effects and whether the treatment delays surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.